ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Translational Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1615618
Investigating the Feasibility of Machine Learning to Guide Personalized Red Blood Cell (RBC) Transfusion: Analyzing the Heterogeneity of RBC Transfusion in Septic Patients with Hemoglobin Levels of 7-9 g/dL Based on the Causal Forest Model
Provisionally accepted- 1Jiangdu People's Hospital Affiliated to Yangzhou University, Yangzhou City, China
- 2Yangzhou Jiangdu Traditional Chinese Medicine Hospital, Yangzhou City, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: This study utilized the causal forest algorithm to explore the heterogeneity of treatment effects of low-dose red blood cell (RBC) transfusion on the 90-day survival rate of sepsis patients with hemoglobin (Hb) levels of 7-9 g/dL to develop personalized transfusion strategies. Methods: The data of patients the met the Sepsis-3 criteria with a minimum Hb level of 7-9 g/dL were obtained from the MIMIC-IV and MIMIC-III databases and divided into RBC transfusion and non-transfusion groups. Patients in both groups were paired using a propensity score matching analysis (PSM) after which a causal forest model was constructed using MIMIC-IV data. The model's accuracy was analyzed using out-of-bag data. Individual treatment effects (ITE) of MIMIC-III patients were predicted and categorized into four subgroups: Quantile1 to Quantile4, based on the effect size. Kaplan-Meier survival curves were established for each Quantile to determine the survival rates. Results: The MIMIC-IV and MIMIC-III database comprised 1,652 and 868 patients, with 826 (50%) and 434 (50%) in the RBC transfusion group, respectively, after PSM. The mean prediction coefficient estimated by the causal forest was 1.00 with a standard error of 0.57, while the differential forest prediction coefficient was 1.64 with a standard error of 0.48, demonstrating the model's ability to effectively identify differences in the impact of transfusion on survival rates among individuals. There was significant heterogeneity in the ITE among patients in the MIMIC-III validation cohort. Moreover, the ITE values were divided into Quantile1: -5.4% (-8.0%, -3.9%), Quantile2: -2.1% (-2.6%, -1.7%), Quantile3: -0.5% (-0.1%, +0.1%), and Quantile 4: +3.6% (+2.0%, +6.6%). The Kaplan-Meier curves and the log-rank test demonstrated that the RBC transfusion decreased the survival of patients in Quantile1 (p<0.001) and Quantile2 (p=0.011) but increased the survival of patients in Quantile4 (p<0.001). Conclusion: RBC transfusions among sepsis patients with Hb levels of 7-9 g/dL exhibit heterogenous treatment effects, which reduces the mortality of patients with high ITE. Although the causal forest model can guide personalized transfusion in these cases, randomized controlled trials are needed to validate these findings.
Keywords: Sepsis, Causal forest, red blood cell transfusion, heterogeneity analysis, personalized treatment
Received: 21 Apr 2025; Accepted: 13 Aug 2025.
Copyright: © 2025 Yang, Yuan, He, Yu, gu, Ding and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Qihong Chen, Jiangdu People's Hospital Affiliated to Yangzhou University, Yangzhou City, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.